Aeglea BioTherapeutics, Inc. 4
4 · Aeglea BioTherapeutics, Inc. · Filed Apr 12, 2016
Insider Transaction Report
Form 4
TYLER JOSEPH E
VP, Manufacturing
Transactions
- Conversion
Common Stock
2016-04-12+31,260→ 42,428 total - Conversion
Series A Preferred Stock
2016-04-12−22,857→ 0 totalExercise: $0.00→ Common Stock (22,857 underlying) - Conversion
Series B Preferred Stock
2016-04-12−8,403→ 0 totalExercise: $0.00→ Common Stock (8,403 underlying)
Footnotes (1)
- [F1]In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.